{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:10:49Z","timestamp":1792239049784,"version":"4.4.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-dose chemotherapy and\u00a0autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primary refractory (rel\/ref) chemorefractory diffuse large B-cell lymphoma. Only 50% of patients are cured with this approach. We investigated\u00a0safety and efficacy of\u00a0CD19-specific chimeric antigen receptor (CAR) T cells administered following HDT-ASCT. Eligibility for this study includes poor-risk rel\/ref aggressive B-cell non-Hodgkin lymphoma chemosensitive\u00a0to salvage therapy with: (1) positron emission tomography\u2013positive\u00a0disease or (2) bone marrow involvement. Patients underwent standard\u00a0HDT-ASCT followed by 19-28z CAR T cells on days +2 and +3. Of 15 subjects treated on study, dose-limiting toxicity was observed at both dose levels (5\u00a0\u00d7\u00a0106\u00a0and 1\u00a0\u00d7\u00a0107\u00a019-28z CAR T per kilogram). Ten of 15 subjects experienced CAR T-cell\u2013induced neurotoxicity and\/or cytokine release syndrome (CRS), which were associated with greater CAR T-cell persistence (P\u00a0= .05) but not peak CAR T-cell expansion. Serum interferon-\u03b3\u00a0elevation\u00a0(P\u00a0&amp;lt; .001) and possibly interleukin-10 (P\u00a0= .07) were associated with toxicity. The 2-year progression-free survival (PFS) is 30% (95% confidence interval, 20% to 70%).\u00a0 Subjects given decreased naive-like (CD45RA+CCR7+) CD4+\u00a0and CD8+\u00a0CAR T cells experienced superior PFS (P\u00a0= .02 and .04, respectively). There was no association between CAR T-cell peak expansion, persistence, or cytokine changes and PFS. 19-28z CAR T cells following HDT-ASCT were associated with a high incidence of reversible neurotoxicity and CRS. Following HDT-ASCT, effector CD4+\u00a0and CD8+\u00a0immunophenotypes may improve disease control. This trial was registered at\u00a0www.clinicaltrials.gov\u00a0as #NCT01840566.<\/jats:p>","DOI":"10.1182\/blood.2018883421","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T04:15:13Z","timestamp":1562040913000},"page":"626-635","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":79,"title":["CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma"],"prefix":"10.1182","volume":"134","author":[{"given":"Craig S.","family":"Sauter","sequence":"first","affiliation":[{"name":"Department of Medicine and"},{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Senechal","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Michael G. Harris Cell Therapy and Cell Engineering Facility,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Rivi\u00e8re","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Michael G. Harris Cell Therapy and Cell Engineering Facility,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Bernal","sequence":"additional","affiliation":[{"name":"Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Michael G. Harris Cell Therapy and Cell Engineering Facility,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Purdon","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malloury","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashvin N.","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria Z.","family":"Szenes","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":false,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Michael G. Harris Cell Therapy and Cell Engineering Facility,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig H.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Matasar","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Curran","sequence":"additional","affiliation":[{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Pediatrics, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-8025","authenticated-orcid":false,"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY;"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2020021109250487000_B1","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"13","key":"2020021109250487000_B2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","article-title":"Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial","volume":"31","author":"Vose","year":"2013","journal-title":"J Clin Oncol"},{"issue":"36","key":"2020021109250487000_B3","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","article-title":"Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma","volume":"30","author":"Gisselbrecht","year":"2012","journal-title":"J Clin Oncol"},{"issue":"16","key":"2020021109250487000_B4","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","article-title":"Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma","volume":"125","author":"Sauter","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2020021109250487000_B5","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/bjh.12176","article-title":"Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era","volume":"160","author":"Armand","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"2020021109250487000_B6","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/cncr.23861","article-title":"Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma","volume":"113","author":"Derenzini","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"2020021109250487000_B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2010.08162.x","article-title":"Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy","volume":"150","author":"Dickinson","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"2020021109250487000_B8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.bbmt.2006.12.452","article-title":"The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin\u2019s lymphoma in second complete or partial remission","volume":"13","author":"Lerner","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"355","key":"2020021109250487000_B9","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"16","key":"2020021109250487000_B10","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"26","key":"2020021109250487000_B11","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021109250487000_B12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"issue":"224","key":"2020021109250487000_B13","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"26","key":"2020021109250487000_B14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"2020021109250487000_B15","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"32","key":"2020021109250487000_B16","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020021109250487000_B17","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1172\/JCI30414","article-title":"Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells","volume":"117","author":"Wrzesinski","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"2020021109250487000_B18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"10","key":"2020021109250487000_B19","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","article-title":"Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus","volume":"53","author":"Meignan","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"177","key":"2020021109250487000_B20","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"2","key":"2020021109250487000_B21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","article-title":"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"J Immunother"},{"issue":"4","key":"2020021109250487000_B22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020021109250487000_B23","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"2020021109250487000_B24","volume-title":"A Language and Environment for Statistical Computing","author":"R Core Team","year":"2016"},{"issue":"1","key":"2020021109250487000_B25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel [published correction appears in J Hematol Oncol. 2018;11(1):81]","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"27","key":"2020021109250487000_B26","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021109250487000_B27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2020021109250487000_B28","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2020021109250487000_B29","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2020021109250487000_B30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br J Haematol"},{"issue":"9","key":"2020021109250487000_B31","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"},{"issue":"10","key":"2020021109250487000_B32","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"2020021109250487000_B33","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent to treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2020021109250487000_B34","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/leu.2017.39","article-title":"Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia","volume":"31","author":"Rossig","year":"2017","journal-title":"Leukemia"},{"issue":"544","key":"2020021109250487000_B35","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"key":"2020021109250487000_B36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.03.012","article-title":"Development of CAR T cells designed to improve antitumor efficacy and safety","volume":"178","author":"Jaspers","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"4","key":"2020021109250487000_B37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"issue":"12","key":"2020021109250487000_B38","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"6","key":"2020021109250487000_B39","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"2020021109250487000_B40","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2020021109250487000_B41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021109250487000_B42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2020021109250487000_B43","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"7","key":"2020021109250487000_B44","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2020021109250487000_B45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2020021109250487000_B46","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2020021109250487000_B47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2020021109250487000_B48","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.0105-2896.2010.00899.x","article-title":"Plasticity in programming of effector and memory CD8 T-cell formation","volume":"235","author":"Arens","year":"2010","journal-title":"Immunol Rev"},{"issue":"11","key":"2020021109250487000_B49","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/7\/626\/1554342\/blood883421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/7\/626\/1554342\/blood883421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T13:49:23Z","timestamp":1721483363000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/7\/626\/260726\/CD19-CAR-T-cells-following-autologous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2018883421","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,15]]}}}